Odyssey Therapeutics (NASDAQ:ODTX) Issues Quarterly Earnings Results

Odyssey Therapeutics (NASDAQ:ODTX) released its quarterly earnings results on Wednesday. The company reported ($1.74) earnings per share for the quarter, FiscalAI reports.

Odyssey Therapeutics Stock Performance

Shares of Odyssey Therapeutics stock traded up $0.66 on Thursday, reaching $21.55. The company had a trading volume of 123,152 shares, compared to its average volume of 254,668. The firm’s 50-day simple moving average is $17.78. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $22.11.

Analysts Set New Price Targets

A number of research analysts have recently commented on ODTX shares. JPMorgan Chase & Co. began coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 target price for the company. Wall Street Zen cut shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. Zacks Research raised shares of Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Oppenheimer reiterated an “outperform” rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Finally, Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Buying and Selling

In other news, Director Nan (Ln) Li bought 1,111,111 shares of Odyssey Therapeutics stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the purchase, the director owned 3,333,516 shares in the company, valued at $60,003,288. The trade was a 50.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Dimension Capital Ii, L.P. bought 1,111,111 shares of the stock in a transaction dated Friday, May 8th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the acquisition, the director directly owned 3,333,516 shares in the company, valued at approximately $60,003,288. The trade was a 50.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 4,183,777 shares of company stock valued at $75,319,986 over the last 90 days.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.